Table 2

Comparison of urinary excretion rates of isoflavonoids and lignans, and blood levels of steroid hormones and SHBG between cases and controls, the Shanghai Breast Cancer Study, 1996–98

Median (25th, 75th percentile)Percentagea differenceP from paired Wilcoxon rank test
Cases (n = 117)Controls (n = 117)
Total isoflavonoidsb,c18.38 (5.36, 44.91)26.41 (8.31, 62.32)−30.40.04
 Daidzeinb5.10 (1.97, 21.30)11.57 (4.02, 26.19)−55.90.03
 Genisteinb2.42 (0.50, 9.37)5.80 (0.96, 13.23)−58.30.12
 Glyciteinb0.56 (0.14, 2.35)1.31 (0.30, 3.37)−57.30.01
Total mammary lignansb,d1.72 (0.32, 4.34)2.64 (0.43, 7.01)−34.80.06
 Enterolactoneb0.20 (0.04, 0.44)0.29 (0.11, 0.68)−31.00.02
 Enterodiolb1.22 (0.14, 3.89)2.11 (0.23, 6.57)−42.20.04
E2 (pg/ml)5.73 (3.82, 13.65)5.73 (3.82, 14.96)0.00.59
E1 (pg/ml)19.10 (9.57, 24.20)17.85 (9.05, 20.65)7.0<0.01
E1-S (ng/ml)1.14 (0.51, 6.68)0.96 (0.48, 6.68)18.80.40
Testotesterone0.20 (0.13, 0.28)0.16 (0.12, 0.22)25.0<0.01
DHEA-S (ng/ml)671.8 (485.5, 988.9)589.8 (404.4, 811.7)13.90.05
SHBG (nmol/liter)74.90 (55.65, 113.95)81.40 (56.40, 121.80)−8.00.81
  • a Expressed as (mediancases − mediancontrols)/mediancontrols.

  • b Expressed as nmoles per mg creatinine.

  • c Including daizein, genistein, glycitein, O-DMA, dihydro-daidzein, and dihydro-genistein.

  • d Including mammary enterolactone and enterodiol.